Erlotinib-induced autophagy in epidermal growth factor receptor mutated non-small cell lung cancer》.pdf

Lung Cancer 81 (2013) 354–361 Contents lists available at ScienceDirect Lung Cancer j o u r n a l h o m e p a g e : w w w. elsev /locate/lung can Erlotinib-induced autophagy in epidermal growth factor receptor mutated non-small cell lung cancer Yuan-yuan Li, Sze-kwan Lam, Judith Choi-wo Mak, Chun-yan Zheng, James Chung-man Ho ∗ Division of Respiratory Medicine, Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong Special Administrative Region a r t i c l e i n f o a b s t r a c t Article history: Purpose: Erlotinib is a commonly used tyrosine kinase inhibitor (TKI) in non-small cell lung cancer Received 29 January 2013 (NSCLC). Autophagy is a catabolic process in response to stress and deprivation of nutrients. This study Received in revised form 16 May 2013 aims to investigate whether autophagy confers acquired resistance to erlotinib treatment in NSCLC. Accepted 20 May 2013 Methods: Four NSCLC cell lines (HCC827, HCC4006, H358 and H1975) with different epidermal growth factor receptor (EGFR) mutation status (exon 19 deletion, exon 19 deletion, wild-type and L858R/T790M Keywords: respectively) were selected. MTT assay, crystal violet staining and Annexin-V assay were performed Erlotinib to determine cell viability and apoptosis. Autophagic proteins were detected by Western blot. Acidic Autophagy Epidermal growth factor receptor